Stocks · Healthcare · Biotechnology
Tarsus Pharmaceuticals, Inc. TARS
$74.46 +2.00% Close, Oct 5, 2026 · NASDAQ · Market cap $3.14B
High qualityLow risk
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $606.3M, up 105.2% from a year earlier, slowing from 129.0% a quarter earlier.
- Operating margin widened to -8.0% from -33.2% a year earlier.
- The stock is in an uptrend: above its 200-day average for 39 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
Growth79Positive
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 10%
- Revenue growth, 3-year CAGRTop 5%
- Revenue growth accelerationBottom 11%
Quality84Strong
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 43%
- Gross marginTop 19%
- Operating marginBottom 49%
- Accruals (lower is better)Top 13%
- Interest coverBottom 40%
Value67Positive
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 34%
- Free-cash-flow yieldTop 29%
- EBITDA / enterprise valueTop 41%
- Sales / enterprise valueBottom 47%
Momentum66Positive
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 37%
- 6-month returnBottom 47%
- 1-year return vs S&P 500Top 39%
- Distance from 52-week highTop 31%
- Trend checklist (0–4)Top 26%
Revisions19Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 16%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 27%
- Upside to consensus price targetBottom 41%
Stability94Exceptional
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 38%
- Maximum drawdown, 3 yearsTop 18%
- Beta vs S&P 500 (lower is better)Top 6%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 129.0% | 105.2% | ↓ |
| Gross margin | 93.4% | 90.6% | ↓ |
| Operating margin | -33.2% | -8.0% | ↑ |
| FCF margin | -29.7% | 10.2% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 105.2% | 129.0% | ↓ | Top 10% |
| Gross margin | 90.6% | 93.4% | ↓ | Top 19% |
| Operating margin | -8.0% | -33.2% | ↑ | Bottom 49% |
| Net margin | -7.7% | -31.1% | ↑ | — |
| Free-cash-flow margin | 10.2% | -29.7% | ↑ | — |
| Return on invested capital | -11.1% | — | Top 43% | |
| Revenue growth, 3-year CAGR | 159.5% | — | Top 5% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -20.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -42.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -5.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.20%
- Shareholder yield
- -0.20%
- Share count change, 1 year
- +2.4%
- Share count change, 3-year CAGR
- +17.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -36.0%
- Average 2-day reaction, last 8
- -0.0%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $103.00
- Target vs current price
- +38.3%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 90%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -124.2% | +6.6% | +14.2% | +35.0% | — |
| May 6, 2026 | +60.2% | -0.4% | -8.0% | -9.7% | -9.2% |
| Feb 23, 2026 | -94.2% | +4.5% | +13.4% | -3.2% | -5.7% |
| Nov 4, 2025 | +14.3% | +2.5% | +4.3% | +13.8% | -7.5% |
| Aug 6, 2025 | -45.5% | +1.2% | +24.8% | +40.3% | +64.1% |
| May 1, 2025 | +7.2% | -3.1% | -8.8% | -16.3% | -19.6% |
| Feb 25, 2025 | +11.8% | -9.3% | -6.2% | +15.0% | -1.4% |
| Nov 13, 2024 | +35.1% | -2.2% | -1.4% | +9.6% | +7.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.43 | -$0.19 | -124.2% | $173.9M |
| May 6, 2026 | -$0.16 | -$0.40 | +60.2% | $162.1M |
| Feb 23, 2026 | -$0.20 | -$0.10 | -94.2% | $151.7M |
| Nov 4, 2025 | -$0.30 | -$0.35 | +14.3% | $118.7M |
| Aug 6, 2025 | -$0.48 | -$0.33 | -45.5% | $102.7M |
| May 1, 2025 | -$0.64 | -$0.69 | +7.2% | $78.3M |
| Feb 25, 2025 | -$0.60 | -$0.68 | +11.8% | $66.4M |
| Nov 13, 2024 | -$0.61 | -$0.94 | +35.1% | $48.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 4.99× | — | — | Bottom 47% |
| Free-cash-flow yield | 1.96% | — | — | Top 29% |
| Earnings yield | -1.46% | — | — | Top 34% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 45
- Days above the 200-day average
- 39
- 50-day average slope (20 days)
- +10.3%
- 200-day average slope (20 days)
- -0.3%
- Distance from 50-day average
- +2.4%
- Distance from 200-day average
- +8.7%
- RSI (14)
- 46.8
- Relative volume
- 0.96×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 48.8%
- Volatility vs own 5-year history
- 34th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.21
- Correlation with S&P 500
- 0.06
- Current drawdown from 1-year high
- -18.0%
- Maximum drawdown, 3 years
- -45.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 18, 2020 | May 6, 2022 | -77.7% | 347 days | 643 days (Nov 26, 2024) |
| Dec 24, 2025 | Jul 14, 2026 | -32.0% | 136 days | 36 days (Sep 2, 2026) |
| Feb 5, 2025 | Jul 31, 2025 | -31.8% | 121 days | 16 days (Aug 22, 2025) |
| Nov 5, 2020 | Nov 25, 2020 | -26.2% | 14 days | 7 days (Dec 7, 2020) |
| Oct 21, 2020 | Oct 29, 2020 | -21.8% | 6 days | 4 days (Nov 4, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.14B
- EPS, diluted (TTM)
- -$1.09
- Revenue (TTM)
- $606.3M
- 52-week range
- $53.89 – $91.53
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $57.0M | $25.8M | $17.4M | $183.0M | $451.4M |
| Gross profit | $55.0M | $24.9M | $15.9M | $170.1M | $420.7M |
| Operating income | -$12.2M | -$62.7M | -$143.2M | -$120.6M | -$71.0M |
| Net income | -$13.8M | -$62.1M | -$135.9M | -$115.6M | -$66.4M |
| EPS (diluted) | -$0.67 | -$2.52 | -$4.62 | -$3.07 | -$1.59 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M | $66.4M | $78.3M | $102.7M | $118.7M | $151.7M | $162.1M | $173.9M |
| Net income | -$23.4M | -$23.1M | -$25.1M | -$20.3M | -$12.6M | -$8.4M | -$7.0M | -$18.6M |
| EPS (diluted) | -$0.61 | -$0.60 | -$0.64 | -$0.48 | -$0.30 | -$0.20 | -$0.16 | -$0.43 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $3.7M | -$49.0M | -$117.5M | -$83.0M | -$12.5M |
| Capital expenditure | -$586,000 | -$506,000 | -$5.5M | -$1.6M | -$9.9M |
| Free cash flow | $3.2M | -$49.5M | -$123.0M | -$84.6M | -$22.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $21,000 | $74.9M | $120.2M | $115.1M | $143.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $449.7M
- Total assets
- $611.1M
- Total liabilities
- $264.4M
- Total debt
- $88.7M
- Net debt
- -$115.9M
- Shareholders’ equity
- $346.7M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 6,127,884
- Days to cover
- 6.64
- Change vs previous report
- +1.9%
FINRA short interest, settlement date Sep 15, 2026.